Fujian Boro Pharmaceutical Research Co., Ltd.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the pharmacokinetic behavior of the test preparation Lercanidipine Hydrochloride Tablets (Specification: 10 mg, licensee: Fujian Province Baonuo Pharmaceutical Research and Development Co., Ltd.) and the reference preparation Lercanidipine Hydrochloride Tablets (Specification: 10 mg, licensee: Recordati S.P.A., trade name: Zainingping®) in healthy subjects after oral administration in the fasting state, and evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation Lercanidipine Hydrochloride Tablets and the reference preparation Lercanidipine Hydrochloride Tablets in healthy subjects in the fasting state.

Primary objective: To compare the differences in absorption extent and absorption rate of pregabalin sustained-release tablets (specification: 165 mg) provided by Fujian Baonuo Pharmaceutical Research and Development Co., Ltd. and original pregabalin sustained-release tablets (trade name: Lyrica®CR, specification: 165 mg) certified by UPJOHN US 2 LLC in healthy Chinese population under fasting and postprandial administration conditions using a single-center, randomized, open, two-period crossover, single-dose administration design. Secondary objective: To evaluate the safety of pregabalin sustained-release tablets (specification: 165 mg) provided by Fujian Baonuo Pharmaceutical Research and Development Co., Ltd. and original pregabalin sustained-release tablets (trade name: Lyrica®CR, specification: 165 mg) certified by UPJOHN US 2 LLC under fasting and postprandial conditions.

Primary objective: To compare the differences in absorption degree and speed between Mosapride Citrate Tablets (Specification: 5 mg (based on anhydrous mosapride citrate)) provided by Fujian Baonuo Pharmaceutical Research and Development Co., Ltd. and Mosapride Citrate Tablets (Trade name: Gasqing®, Specification: 5 mg (based on anhydrous mosapride citrate)) certified by Sumitomo Pharma Co., Ltd. in healthy people under fasting administration conditions. Secondary objective: To evaluate the safety of Mosapride Citrate Tablets (Specification: 5 mg (based on anhydrous mosapride citrate)) provided by Fujian Baonuo Pharmaceutical Research and Development Co., Ltd.